Effectiveness of Electroconvulsive therapy in patients with Treatment Resistant Schizophrenia: A retrospective study

• Published in: Psychiatry research Vol. 249; pp. 349 - 353
• Main Authors: Grover, Sandeep, Chakrabarti, Subho, Hazari, Nandita, Avasthi, Ajit
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.03.2017
• Subjects: Adolescent; Adult; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - therapeutic use; Clozapine; Clozapine - administration & dosage; Clozapine non-response; Combined Modality Therapy - methods; Electroconvulsive therapy; Electroconvulsive Therapy - methods; Electroconvulsive Therapy - psychology; Female; Humans; Male; Middle Aged; Psychiatry; Retrospective Studies; Schizophrenia; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Schizophrenia - therapy; Schizophrenic Psychology; Treatment Outcome; Treatment-resistant; Young Adult; clozapine; clozapine non-response; electroconvulsive therapy; schizophrenia; treatment-resistant; Treatment-resistant; Schizophrenia; Clozapine non-response; Electroconvulsive therapy; Clozapine
• ISSN: 0165-1781; 1872-7123
• DOI: 10.1016/j.psychres.2017.01.042

Abstract This study aimed to evaluate the effectiveness of electroconvulsive therapy (ECT) among patients with treatment resistant schizophrenia (TRS). Records of patients who had received ECT were reviewed to identify patients with TRS who were administered ECT in combination with clozapine. Socio-demographic, clinical data and ECT details were extracted. The most common diagnosis was of paranoid schizophrenia (49%) followed by undifferentiated schizophrenia (36%). A-fifth (22%) of the patients were judged to have poor response to clozapine. The mean number of ECTs given were 13.97 (SD-7.67) and mean clozapine dose was 287.5 mgs/day (SD- 100.1). About two-thirds (63%) of the patients showed > 30% reduction in scores on different symptom-rating scales with combined use of clozapine and ECT. Among clozapine non-responders, approximately 69% responded to the combination. Post-ECT rise in blood pressure was the most common side effect (16.9%) followed by prolonged seizures (7%). Long-term follow-up data was available for 47 out of the 59 patients. More than two-third (N=34; 72%) followed-up for an average of 30 months (SD 32.3; range: 1–120), maintained well with continued clozapine treatment. To conclude, results of this study further endorse the effectiveness, safety and long-term benefits of the clozapine-ECT combination in TRS and clozapine-refractory schizophrenia.